Get started
Author

Rayann Atway

Observed name: Atway, Rayann
Institution: Cone Health
ORCID: 0000-0002-4286-6254
Observed ORCID: 0000-0002-4286-6254
OpenAlex ID: A5091799664
Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer
2019 · S. Thomas Hennigan, Shana Y. Trostel, et al. · JCO Precision Oncology · 91
Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy
2021 · Scott Wilkinson, Huihui Ye, et al. · European Urology · 88
A case report of multiple primary prostate tumors with differential drug sensitivity
2020 · Scott Wilkinson, Stephanie A. Harmon, et al. · Nature Communications · 36
PDF
MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity
2020 · Nichelle C. Whitlock, Shana Y. Trostel, et al. · Oncogene · 34
PDF
Localized high-risk prostate cancer harbors an androgen receptor activity–low subpopulation susceptible to HER2 inhibition
2025 · Scott Wilkinson, Anson T. Ku, et al. · Journal of Clinical Investigation · 9
PDF
Clinical practice guidelines for adolescent and young adult cancer: A literature review.
2024 · Rayann Atway, Dawn Ritzwoller, et al. · Journal of Clinical Oncology · 2
PDF
Clinical Practice Guidelines for the Care of Adolescents and Young Adults (AYAs) with Cancer: a Scoping Review
2026 · Jacob Newton Stein, Emily Ruth Haines, et al. · Current Oncology Reports · 1
PDF
Abstract B021: Examining the role of HER2 signaling in promoting prostate cancer proliferation in an androgen receptor-low environment
2023 · Scott Wilkinson, Anson Ku, et al. · Cancer Research
Multiple primary prostate tumors with differential drug sensitivity.
2020 · Scott C. Wilkinson, Huihui Ye, et al. · Journal of Clinical Oncology
Abstract 2510: Combining genetic and histopathologic features to predict response to anti-androgen therapy in aggressive prostate cancer
2019 · Scott Wilkinson, Huihui Ye, et al. · Cancer Research
Abstract 2510: Combining genetic and histopathologic features to predict response to anti-androgen therapy in aggressive prostate cancer
2019 · Scott Wilkinson, Huihui Ye, et al. · Molecular and Cellular Biology / Genetics
Abstract 2606: Genetic contribution of MYC to the development of primary prostate cancer
2019 · Nichelle C. Whitlock, Shana Trostel, et al. · Molecular and Cellular Biology / Genetics
Abstract 2606: Genetic contribution of MYC to the development of primary prostate cancer
2019 · Nichelle C. Whitlock, Shana Trostel, et al. · Cancer Research
Molecular and imaging correlates of exceptional pathologic response to neoadjuvant ADT plus enzalutamide.
2019 · Adam G. Sowalsky, Scott Wilkinson, et al. · Journal of Clinical Oncology
Abstract B058: Genetic contribution of MYC to the development of primary prostate cancer
2018 · Nichelle C. Whitlock, Rayann Atway, et al. · Cancer Research
Molecular and histopathologic correlates of imaging and biological responses to neoadjuvant GnRH agonist plus enzalutamide for high risk prostate cancer.
2018 · Adam G. Sowalsky, Scott Wilkinson, et al. · Journal of Clinical Oncology
Works count: 17
Citation count: 263
H-index: 5
I10-index: 4
Year
Topic
Type